Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin

Clinical Immunology : the Official Journal of the Clinical Immunology Society
Yulia VugmeysterJames G Krueger

Abstract

Therapeutic administration of efalizumab, a humanized antibody to CD11a, induces a marked but reversible increase of peripheral lymphocytes in psoriasis patients. In this study, 13 patients were treated with 12 weekly subcutaneous doses (2 mg/kg/week) of efalizumab, and all 13 patients had increases in leukocyte counts. This increased white blood cell count was mainly due to a 3- to 4-fold increase in the number of circulating CD3(+) lymphocytes during active treatment. Both naive and memory populations of CD4(+) and CD8(+) lymphocytes in the peripheral blood increased, with the largest increase observed in memory CD8(+) T cells. This CD8(+) memory T cell subset is a prominent T cell population found in psoriatic skin. An increase in Type 1 (IFN-gamma producing) T cells was also observed during treatment. Both components of LFA-1, CD11a and CD18, were downregulated during treatment, and surprisingly the integrins CD11b and beta 7 were similarly reduced. We conclude that efalizumab most likely blocks cutaneous entry of memory CD8(+) T cells, a highly disease-relevant cell population. The relatively smaller increase in naive peripheral blood T cells could be attributed to reduced trafficking of naive T cells.

Citations

Aug 13, 2005·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·J C Prinz
Apr 25, 2006·Journal of Cutaneous Medicine and Surgery·Neil H ShearVincent Ho
Nov 21, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Heinz Wiendl
Nov 28, 2007·The Journal of Experimental Medicine·Lisa C ZabaJames G Krueger
Oct 11, 2005·Annual Review of Cell and Developmental Biology·Cornelia HalinUlrich H von Andrian
Nov 26, 2010·The Journal of Clinical Investigation·Idelberto R BadellChristian P Larsen
Aug 20, 2005·BMC Dermatology·Michelle A LowesRoss St C Barnetson
Feb 28, 2007·BMC Dermatology·Michelle A LowesJames G Krueger
Dec 29, 2005·Proceedings of the National Academy of Sciences of the United States of America·Michelle A LowesJames G Krueger
Dec 4, 2013·Journal of Neurovirology·Sarah Beltrami, Jennifer Gordon
Jul 25, 2008·The Journal of Dermatological Treatment·Else N KopPeter C M Van de Kerkhof
Sep 28, 2013·Expert Opinion on Therapeutic Targets·Tej Pratap SinghJoshua M Farber
Oct 27, 2006·Expert Opinion on Emerging Drugs·Gino A Vena, Nicoletta Cassano
Mar 1, 2006·Expert Opinion on Drug Safety·Noah Scheinfeld
Nov 10, 2015·The Journal of Investigative Dermatology. Symposium Proceedings·Scott C Kachlany
Feb 9, 2011·Experimental Cell Research·Kristine E Nograles, James G Krueger
Mar 19, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Werner M KuscheiPeter Steinberger
Nov 4, 2010·Journal of Dermatological Science·Frieder KoszikGeorg Stingl
Feb 2, 2008·The Journal of Investigative Dermatology·Emma Guttman-YasskyJames G Krueger
Aug 30, 2008·Clinics in Dermatology·Yi-Yang Yvonne LiMichael P Schön
Feb 24, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Benjamin F Chong, Henry K Wong
Apr 9, 2008·Dermatologic Therapy·Julia Tzu, Francisco Kerdel
Jan 26, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M R Nicolls, R G Gill
Jul 14, 2007·Current Opinion in Pharmacology·Emily M Berger, Alice B Gottlieb
Jun 26, 2007·Skin Pharmacology and Physiology·B BonnekohH Gollnick
Jun 11, 2015·PloS One·Francesca Isabella De-SimoneIlker Kudret Sariyer
Aug 30, 2006·Advances in Immunology·Donald E StauntonW Michael Gallatin
Sep 11, 2016·Biochemical Pharmacology·Riccardo V MancusoGabriele Weitz-Schmidt
Oct 1, 2012·Therapeutic Advances in Drug Safety·Fariha Zaheer, Joseph R Berger
Feb 23, 2007·Nature·Michelle A LowesJames G Krueger
Oct 12, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joseph R Berger
Jan 18, 2020·Expert Opinion on Biological Therapy·Alvise SernicolaMauro Alaibac
Jan 28, 2020·British Journal of Pharmacology·Riccardo V MancusoGabriele Weitz-Schmidt
Jun 27, 2013·Experimental Dermatology·Marta FerranLuis F Santamaria-Babí

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.